| SEC Form 4 |  |
|------------|--|
|------------|--|

П

### FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if no longer subject to |
|--|
| Section 16. Form 4 or Form 5           |
| obligations may continue. See          |
| Instruction 1(b).                      |

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

# OMB APPROVAL OMB Number: 3235-0287

|   | hours per response:     | 0.5       |
|---|-------------------------|-----------|
|   | Estimated average burde | en        |
| I |                         | 3233-0201 |

|   | ss of Reporting Perso | n*       | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br>Unum Therapeutics Inc. [UMRX] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) |                                      |                          |  |  |
|---|-----------------------|----------|---|---|--------------------------------------|--------------------------|--|--|
| Ettenberg Seth  |                       |          |   |   | Director                             | 10% Owner                |  |  |
| (Loot)  | (Eirot)               | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year)                                    | X   | Officer (give title<br>below)        | Other (specify<br>below) |  |  |
| (Last) (First) (Middle)<br>C/O UNUM THERAPEUTICS INC.<br>200 CAMBRIDGE PARK DRIVE, SUITE 3100 |                       |          | 10/25/2018  |   | Chief Scientific                     | Officer                  |  |  |
|   |                       |          |   |   |                                      |                          |  |  |
|   |                       |          | 4. If Amendment, Date of Original Filed (Month/Day/Year)                            | 6. Indiv<br>Line)   | idual or Joint/Group Filin           | g (Check Applicable      |  |  |
| (Street)  |                       | 00140    |   | X   | X Form filed by One Reporting Person |                          |  |  |
| CAMBRIDGE   | MA                    | 02140    |   |   | Form filed by More tha<br>Person     | n One Reporting          |  |  |
| (City)  | (State)               | (Zip)    |   |   |                                      |                          |  |  |

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 3.<br>Transa<br>Code (<br>8) |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and 5) |               |                                | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------|--|---|------------------------------|---|--|---------------|--------------------------------|---|---|---|
|                                 |  |   | Code                         | v | Amount   | (A) or<br>(D) | Price                          | Transaction(s)<br>(Instr. 3 and 4)  |   | (1150.4)  |
| Common Stock                    | 10/25/2018                                 |   | М                            |   | 11,485   | Α             | \$0.18                         | 11,485  | D   |   |
| Common Stock                    | 10/25/2018                                 |   | <b>S</b> <sup>(1)</sup>      |   | 11,485   | D             | <b>\$8.4633</b> <sup>(2)</sup> | 0   | D   |   |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transaction<br>8)<br>5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D) (Instr.<br>3, 4 and 5) |   | nsaction<br>le (Instr.<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D) (Instr. |        | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | Expiration Date of Securities |  | of Securities<br>Underlying<br>Derivative Security |         | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|--|---|---|---|--|--------|--|--------------------|-------------------------------|--|--|---------|---|--|--|--|
|   |   |  |   | Code  | v | (A)  | (D)    | Date<br>Exercisable  | Expiration<br>Date | Title                         | Amount<br>or<br>Number<br>of<br>Shares |  |         |   |  |  |  |
| Stock<br>Option<br>(Right to<br>Buy)                | \$0.18  | 10/25/2018                                 |   | М   |   |  | 11,485 | (3)  | 01/28/2025         | Common<br>Stock               | 11,485                                 | \$0.00   | 375,085 | D   |  |  |  |

#### Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$8.06 to \$8.67, inclusive. The reporting person undertakes to provide to Unum Therapeutics Inc., any security holder of Unum Therapeutics Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. 25% of the shares vests on September 3, 2015, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.

Remarks:

| <u>/s/ Amoli Pandya, as Attorney-</u> | 10/20/2010 |
|---------------------------------------|------------|
| in-Fact                               | 10/29/2010 |

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.